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Malignant Hyperthermia
Alexandra McGuire, BSN, RN CCRN-CMC
Otterbein University, Westerville, Ohio
Introduction
Malignant Hyperthermia (MH) is a rare but
life-threatening, genetic condition that can
manifest when a patient is exposed to certain
inhalation agents used in anesthesia as well as
the depolarizing muscle relaxant
succinylcholine (Rosenberg, Pollock,
Schiemann, Bulger, & Stowell, 2015, p. 1).
MH is an autosomal dominant trait with
incomplete penetrance that has been found in
“approximately 1:40,000 adults” (Creech &
Zhang, 2019, p. 1). The RYR1 gene, which
encodes for calcium release channels in the
sarcoplasmic reticulum, is the most prevalent
gene mutation found in MH patients (Miller et
al., 2018, p. 945).

Importance
MH can develop during or after a surgical
procedure and if left untreated, can cause
major organ system damage and death
(Seifert, Wahr, Pace, Cochrane, & Bagnola,
2014, p. 189). Creating awareness of this rare
genetic condition allows for quicker
interventions in reversing MH.
Due to the increased awareness, genetic
testing, and MH protocol, the incidence of
death due to MH “has decreased in the last
thirty years” (Rosenberg et al., 2015, p. 13).
More specifically, MH mortality has been
reduced from “80% to 1.4%” (Rosenberg et
al., 2015, p. 13). The continued awareness
and research of MH should be maintained to
effectively decrease the mortality rates of
MH.

Case Report
(Mullins, 2018)
J.M., a 24-year-old female, presented for
an elective bilateral breast reduction surgery.
The preoperative evaluation reported no
abnormalities, but J.M. was adopted so there
was no known family medical history.
Anesthesia induction was performed, and vital
signs remained stable. J.M. was mechanically
ventilated and maintained with desflurane,
fentanyl, and vecuronium.
Twenty-five minutes after induction, J.M.
started to exhibit masseter spasm and the
surgeon noted muscle rigidity.
Simultaneously, J.M. became tachycardiac,
hypertensive, dark color urine was noted, and
her end-tidal carbon dioxide (EtCO2) rose to
58 mmHg. Her forehead temperature probe
remained constant at 36.9 ˚C. The anesthesia
provider suspected the onset of MH and called
for additional staff members.

Epidemiology
• Incidence of MH episodes (Creech & Zhang,
2019, p. 1):
• 1:40,000 in adults
• 1:15,000 in pediatrics
• On average, patients require exposure to three
anesthetic events before a triggering event
(Rosenberg et al., 2015, p. 2).
• All ethnic groups are affected (Rosenberg et
al., 2015, p. 2).
• Reactions develop more frequently in males
than in females (Rosenberg et al., 2015, p. 2).
• The average age of occurrence is 18.3 years
(Rosenberg et al., 2015, p. 2).
• Three genes have been associated with MH
susceptibility (Miller et al., 2018, p. 945):
• RYR1 gene
• CACNA1S gene
• STAC3 gene
• MH genes are inherited by an autosomal
dominant pattern with incomplete penetrance
(Creech & Zhang, 2019, p. 1).

Excitation-contraction
Coupling Process
1. Acetylcholine binds to postsynaptic nicotinic
acetylcholine receptors (nAChR) located on the
sarcolemma (skeletal muscle cell membrane)
(Mullins, 2018, p. 583).
2. Activation of nonselective cation channels
depolarize the sarcolemma and the action
potential travels down the transverse tubule (ttubule) system (Mullins, 2018, p. 583).
3. L-type voltage-gated calcium (Cav1.1) channels
located in the t-tubule undergo a conformational
change due to depolarization. Cav1.1 channels
signal the type 1 ryanodine receptors (RyR1) to
open and release calcium (Ca2+) from the
sarcoplasmic reticulum (SR) (Mullins, 2018, p.
583).
4. The influx of extracellular Ca2+ through Cav1.1
channels and intracellular release of Ca2+ from
the SR activate muscle contraction by Ca2+
binding to troponin (Mullins, 2018, p. 583).

Underlying Pathophysiology
• Three genetic mutations are linked to MH susceptibility
(Miller et al., 2018, p. 945):
• RyR1 gene: encodes the channel that releases Ca2+
from the SR.
• CACNA1S gene: encodes the main subunit of the ttubule voltage sensor.
• STAC3 gene: encodes a protein responsible for
directing the voltage sensor into the correct t-tubule
location and a direct role in excitation-contraction
coupling.
• Signs and symptoms of MH are related to the
uncontrolled release of intracellular Ca2+ from the SR
(Rosenberg et al., 2015, p. 4).
• Increased intracellular Ca2+ causes abnormal skeletal
muscle metabolism manifesting as (Rosenberg et al.,
2015, p. 4):
• Muscle contraction
• Increased oxygen consumption
• Increased carbon dioxide production
• ATP hydrolysis
• Heat production

• Triggering agents for MH (Seifert et al., 2014, p.
192):
• Volatile anesthetics:
• Desflurane
• Enflurane
• Isoflurane
• Sevoflurane
• Depolarizing neuromuscular blockers (NMB):
• Succinylcholine
• Triggering agents' effect on Ca2+ release (Klingler
et al., 2014, p.4):
• Volatile anesthetics
• Act directly on RyR1 channels to stimulate
the release of Ca2+ from the SR.
• Succinylcholine
• Acts indirectly by activating the nAChR
resulting in continuous cation influx.
• Cation influx causes continuous
depolarization which allows action
potentials to activate the Cav1.1 channels
leading to RyR1 channel activation.

Late Symptoms

Tachycardia

Hyperthermia

Gradual rise in
EtCO2, despite
increase ventilation

Disseminated
intravascular
coagulation (DIC)

Muscle rigidity

Rhabdomyolysis

Masseter spasm

Cardiac
dysrhythmias

Tachypnea

Hyperkalemia

Sweating

• Dantrolene is the only drug known to treat MH
(Rosenberg et al., 2015, p. 10):
• Binds to specific sites on the RyR1 protein
and reduces channel activity.
• Available in:
• Dantrium (20 mg vial), which requires
60 mL of sterile water to prepare.
• Ryanodex (250 mg ampoule), which
requires 5 mL of sterile water to
prepare.

Clinical Resources

• MH Carts (Seifert et al., 2014, p. 194):
• Available in some facilities.
• Contains all the necessary supplies to
manage an MH crisis.

Figure 3. Triggering agents of MH mechanism of action (Klingler et al., 2014, p. 3)

Cardiac arrest

Significance of Pathophysiology

Figure 1. Signs and symptoms of MH
(Rosenberg et al., 2015, pp. 2-3)
• MH may occur anytime during anesthesia
administration or within one hour of
discontinuation of volatile agents (Rosenberg
et al., 2015, p. 2).
• Some people may only exhibit a few
symptoms, making MH difficult to diagnose
(Mullins, 2018, p. 538).

• Treatment (Seifert et al., 2014, pp. 190-196):
• Discontinuation of trigger agents
• Increase oxygenation and hyperventilate
• Dantrolene 2.5 mg/kg every five minutes
• Cooling measures
• Treat electrolyte disturbance
• Treat rhythm disturbances
• Monitor for recrudescence (24 hours)

• Preventative measures (Rosenberg et al., 2015,
pp. 11-12):
• Preoperative assessment for a history of MH
• Awareness of community genetics.
• Clusters of MH cases located in
Wisconsin, Nebraska, West Virginia,
and Michigan (Mullins, 2018, p. 583).
• Patients with any form of muscle disorder
should receive extra anesthesia caution.
• Patients undergoing general anesthesia
should have core temperature monitoring.
• Total intravenous anesthesia should be
considered for MH suspectable patients.
• Awareness of facility MH protocol.

Signs and Symptoms
Early Symptoms

Implications for
Nursing Care

Figure 2. Excitation-contraction coupling process
(Excitation-contraction coupling, 2019)

• Hypermetabolic state: leads to respiratory and
metabolic acidosis due to the rapid consumption of
energy stores and ATP (Rosenberg et al., 2015, p. 2).

• Muscle rigidity: sustained contracture related to the
increased level of intracellular Ca2+ in skeletal
muscles (Litman, 2019).

• Hyperthermia: a dramatic increase in core temperature
(1-2 ˚C every five minutes) related to the
hypermetabolic state (Rosenberg et al., 2015, p. 2).

• Rhabdomyolysis: the breakdown of skeletal muscle
results in life-threatening hyperkalemia and
myoglobinuria (Litman, 2019).

• DIC: associated with end-stage organ failure and
prolonged hyperthermia (Litman, 2019).

• Cardiac arrhythmias: frequently develop due to
acute hyperkalemia (ie. ventricular ectopy,
tachycardia or fibrillation) (Litman, 2019).

• MHAUS Hotline (Seifert et al., 2014, p. 194):
• (800) 644-9737
• National hotline is available for instruction.

Current Research
• Magnesium (Mg2+) in MH treatment (Choi,
Koenig, & Launikonis, 2017).
• The research concluded that the
administration of dantrolene in the
presence of higher levels of Mg2+ is more
effective than normal, resting Mg2+ levels.
• Dantrolene increases the affinity of the
RyR1 channels for free Mg2+.
• Free Mg2+ helps suppress Ca2+ release
from the RyR1 channels. Thus, decreasing
intracellular Ca2+ accumulation in skeletal
muscles.

Conclusion
Despite the rarity of MH, the genetic
condition must be thoroughly understood by
all health care professionals that interact with
patients who are exposed to anesthetic gases
and succinylcholine. The providers must be
vigilant to certain signs and symptoms and be
ready to respond quickly.
MH crisis requires specific interventions
within certain time frames. The awareness of
MH protocol and treatment allows providers to
deliver optimal care in emergencies. Team
training, simulation, and case studies are
important in preparing health care members
for an MH emergency.
By understanding the pathophysiological
process of MH, providers can differentiate
symptoms of MH from other pathologies.
Comprehension of MH at the cellular level
aids in the knowledge of MH treatment
interventions.
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